close

  
Filter options:

Freebase Commons Metaweb System Types /type

Object is not asserted on this topic.

Freebase Commons Common /common

  • Carvedilol (Solco Healthcare US), manufactured drug form of Carvedilol, 6.25mg/tablet carvedilol film coated tablet, NDC 43547-255

Freebase Commons Business /business

Freebase Commons Medicine /medicine

Section name Section URI Prominent warning Highlight text Subject manufactured drug Section LOINC code
  • false
  • Warnings and Precautions, Intraoperative Floppy Iris Syndrome (5.14)
  • -
  • 43683-2
  • false
  • -
  • -
  • 42229-5
  • false
  • Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of: • Left ventricular dysfunction following myocardial infarction in clinically stable patients (1.2) • Hypertension (1.3)
  • -
  • 34067-9
  • false
  • Take with food. Individualize dosage and monitor during up-titration. (2) • Left ventricular dysfunction following myocardial infarction: Start at 6.25 mg twice daily and increase to 12.5 mg then 25 mg twice daily after intervals of 3 to 10 days. A lower starting dose or slower titration may be used. (2.2) • Hypertension: Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg then 25 mg twice daily over intervals of 1 to 2 weeks. (2.3)
  • -
  • 34068-7
  • false
  • Tablets: 3.125, 6.25, 12.5, 25 mg (3)
  • -
  • 43678-2
  • false
  • • Bronchial asthma or related bronchospastic conditions (4) • Second- or third-degree AV block (4) • Sick sinus syndrome (4) • Severe bradycardia (unless permanent pacemaker in place) (4) • Patients in cardiogenic shock or decompensated heart failure requiring the use of IV inotropic therapy. (4) • Severe hepatic impairment (2.4) • History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol. (4)
  • -
  • 34070-3
  • false
  • • Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue. (5.1) • Bradycardia, hypotension, worsening heart failure/fluid retention may occur. Reduce the dose as needed.( 5.2,5.3, 5.4) • Non-allergic bronchospasm (e.g., chronic bronchitis and emphysema): Avoid β-blockers.(4).  However, if deemed necessary, use with caution and at lowest effective dose. (5.5) • Diabetes: Monitor glucose as β-blockers may mask symptoms of hypoglycemia or worsen hyperglycemia. (5.6)
  • -
  • 43685-7
  • false
  • Most common adverse events (6.1): • Left ventricular dysfunction following myocardial infarction (≥10%): Dizziness, fatigue, hypotension, diarrhea, hyperglycemia, asthenia, bradycardia, weight increase. • Hypertension (≥5.0%) : Dizziness To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
  • -
  • 34084-4
  • false
  • •CYP P450 2D6 enzyme inhibitors may increase and rifampin may decrease carvedilol levels. (7.1, 7.5) • Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (7.2) • Cyclosporine or digoxin levels may increase. (7.3, 7.4) • Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate.  Concomitant use can increase the risk of bradycardia. (7.4) • Amiodarone may increase carvedilol levels resulting in further slowing of the heart rate or cardiac conduction. (7.6) • Verapamil- or diltiazem-type calcium channel blockers may affect ECG and/or blood pressure. (7.7) • Insulin and oral hypoglycemics action may be enhanced. (7.8) See 17 for PATIENT COUNSELING INFORMATION and FDA -approved patient labeling
  • -
  • 34073-7
  • false
  • -
  • -
  • 43684-0

Comments

Hide